News & Updates

A study from Israel presented at ELCC 2026 supports the role of glucose control as a modifiable host factor that could improve the effectiveness of immune checkpoint inhibitors in the treatment of non-small cell lung cancer (NSCLC).

The novel oral, non-peptide glucagon-like peptide-1 receptor agonist (GLP-1 RA) orforglipron gains the upper hand over the current leading oral GLP-1 RA, semaglutide, in individuals with type 2 diabetes (T2D) inadequately controlled on metformin in the phase III ACHIEVE-3 study.

Combination treatment with phentermine-topiramate extended release (ER) and a digitally enhanced lifestyle intervention (DELI) results in a significant and sustained weight reduction, as well as a decrease in cardiovascular disease (CVD) risk, in adults with obesity, reports a study.

In an observational study of two community-based cohorts in Hong Kong, 6.7 percent of individuals with BMI ≥25 kg/m² were reclassified as nonobese after applying the Lancet Commission’s definition of obesity. Individuals with clinical obesity had the highest risk of adverse cardiovascular-kidney-metabolic (CKM) outcomes, while those reclassified as nonobese had an intermediate risk.